Search results
Results from the WOW.Com Content Network
Common side effects include pain and redness around the site of injection (up to 50% of recipients). A small percentage of people develop a mild fever. A small proportion of people develop a severe allergic reaction. [62] In 2016 Health Canada warned of an increased risk of anemia or hemolysis in people treated with eculizumab (Soliris). The ...
Penbraya is a pentavalent conjugate vaccine developed by Pfizer for the prevention of invasive meningococcal disease in people 10 through 25 years of age. [4] Invasive meningococcal disease, caused by the bacterium Neisseria meningitidis, can lead to serious conditions such as meningitis (inflammation of the brain and spinal cord lining) and sepsis. [5]
Pfizer’s new meningococcal vaccine, Penbraya, protects against five kinds of bacteria and could soon be an option that offers people broad protection from meningococcal disease with fewer shots.
According to the U.S. Centers for Disease Control and Prevention, while "any vaccine can cause side effects", [11] most side effects are minor, primarily including sore arms or a mild fever. [11] Unlike most medical interventions vaccines are given to healthy people, where the risk of side effects is not as easily outweighed by the benefit of ...
For premium support please call: 800-290-4726 more ways to reach us
RSV vaccine side effects in older adults . The CDC lists the following as possible side effects of the RSV vaccine: Pain, redness, and swelling where the shot is given. Fatigue. Fever. Headache ...
Meningococcal meningitis is a form of bacterial meningitis. Meningitis is a disease caused by inflammation and irritation of the meninges, the membranes surrounding the brain and spinal cord. In meningococcal meningitis this is caused by the bacteria invading the cerebrospinal fluid and circulating through the central nervous system. Sub ...
A meningococcal polysaccharide vaccine (MPSV4) has been available since the 1970s and is the only meningococcal vaccine licensed for people older than 55. MPSV4 may be used in people 2–55 years old if the MCV4 vaccines are not available or contraindicated. Two meningococcal conjugate vaccines (MCV4) are licensed for use in the U.S. The first ...